DURECT Corporation (DRRX): Price and Financial Metrics


DURECT Corporation (DRRX): $0.85

-0.06 (-6.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DRRX POWR Grades


  • Sentiment is the dimension where DRRX ranks best; there it ranks ahead of 78.23% of US stocks.
  • DRRX's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • DRRX ranks lowest in Momentum; there it ranks in the 12th percentile.

DRRX Stock Summary

  • With a one year PEG ratio of 0.17, Durect Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 1.28% of US stocks.
  • Over the past twelve months, DRRX has reported earnings growth of -2,161.45%, putting it ahead of merely 0.9% of US stocks in our set.
  • As for revenue growth, note that DRRX's revenue has grown -53.58% over the past 12 months; that beats the revenue growth of only 2.93% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Durect Corp are BBI, ATNM, INFI, ZSAN, and SONN.
  • DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.

DRRX Valuation Summary

  • DRRX's EV/EBIT ratio is -12.9; this is 144.03% lower than that of the median Healthcare stock.
  • DRRX's price/sales ratio has moved down 10.8 over the prior 243 months.
  • DRRX's EV/EBIT ratio has moved down 4.8 over the prior 243 months.

Below are key valuation metrics over time for DRRX.

Stock Date P/S P/B P/E EV/EBIT
DRRX 2021-08-31 52.6 4.3 -13.0 -12.9
DRRX 2021-08-30 53.0 4.3 -13.1 -13.0
DRRX 2021-08-27 52.6 4.3 -13.0 -12.9
DRRX 2021-08-26 50.0 4.1 -12.4 -12.2
DRRX 2021-08-25 51.9 4.2 -12.9 -12.7
DRRX 2021-08-24 51.5 4.2 -12.8 -12.6

DRRX Growth Metrics

    The 4 year price growth rate now stands at 92.31%.
  • Its 2 year cash and equivalents growth rate is now at -17.16%.
  • Its year over year net cashflow from operations growth rate is now at -1037.98%.
Over the past 37 months, DRRX's revenue has gone down $4,587,000.

The table below shows DRRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 13.977 -37.311 -36.265
2021-09-30 5.489 -34.58 -24.897
2021-06-30 6.007 -35.905 -24.252
2021-03-31 29.548 -36.553 -0.768
2020-12-31 30.111 -38.704 -0.582
2020-09-30 41.987 -26.347 -9.173

DRRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DRRX has a Quality Grade of C, ranking ahead of 38.99% of graded US stocks.
  • DRRX's asset turnover comes in at 0.065 -- ranking 305th of 680 Pharmaceutical Products stocks.
  • CCXI, LCI, and BHC are the stocks whose asset turnover ratios are most correlated with DRRX.

The table below shows DRRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.065 1.013 -0.373
2021-03-31 0.353 0.982 0.023
2020-12-31 0.412 0.953 0.031
2020-09-30 0.554 0.889 -0.138
2020-06-30 0.624 0.914 0.013
2020-03-31 0.366 0.850 -0.615

DRRX Price Target

For more insight on analysts targets of DRRX, see our DRRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.50 Average Broker Recommendation 1.33 (Strong Buy)

DRRX Stock Price Chart Interactive Chart >

Price chart for DRRX

DRRX Price/Volume Stats

Current price $0.85 52-week high $1.44
Prev. close $0.91 52-week low $0.36
Day low $0.82 Volume 525,348
Day high $0.96 Avg. volume 888,894
50-day MA $0.54 Dividend yield N/A
200-day MA $0.68 Market Cap 193.35M

DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.


DRRX Latest News Stream


Event/Time News Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about Durect Corp that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks

Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | January 13, 2022

DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

Yahoo | January 6, 2022

Analysts Are Bullish on These Healthcare Stocks: Durect (DRRX), Outlook Therapeutics (OTLK)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Durect (DRRX – Research Report), Outlook Therapeutics (OTLK – Research Report) and Aquestive Therapeutics (AQST – Research Report) with bullish sentiments. Durect (DRRX) In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect, with a price target of $6.00. The company's shares closed last Wednesday at $0.97, close to its 52-week low of $0.87. According to TipRanks.com, Arce is a 5-star analyst with an average return of -19.0% and a 25.0% success rate.

Catie Powers on TipRanks | December 23, 2021

DURECT Corporation (DRRX) Sits On Its Hands At $0.97

DURECT Corporation (NASDAQ:DRRX) concluded the trading at $0.97 on Wednesday, December 22 with a fall of -0.31% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.97 and 5Y monthly beta was reading 1.25 with its price kept floating in the range DURECT Corporation (DRRX) Sits On Its Hands At $0.97 Read More »

Stocks Register | December 23, 2021

Disruptive Behavior Disorders Market Size, Share & Growth Analysis To 2027|Eli Lilly and co., DURECT Corporation, Chelsea therapeutics

The global Disruptive Behavior Disorders market was valued at 65.83 Million USD in 2020 and will grow with a CAGR of 3.53% from 2021 to 2027. Due to the sheer rise in the number of behavioural problems, the disruptive disorder

OpenPR | December 22, 2021

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo 88.64%
3-mo 105.46%
6-mo 23.47%
1-year -33.59%
3-year -37.50%
5-year -48.17%
YTD -13.78%
2021 -52.37%
2020 -45.53%
2019 691.67%
2018 -47.83%
2017 -31.34%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5861 seconds.